Along this line, we have previously shown that the functional targeting of bone marrow‐derived monocytes using a mutant, signal‐transduction incompetent VEGFR‐1 significantly slows tumor growth in the same GL261 glioma model as applied in the current study (Kerber et al, 2008). Here, FLT1 is linked to central nervous system cancer.